Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Study Links Virus to Some Cases of Common Skin Cancer

September 11, 2009
Publication
Article
OncologyONCOLOGY Vol 23 No 10
Volume 23
Issue 10

A virus discovered last year in a rare form of skin cancer has also been found in people with the second most common form of skin cancer among Americans, according to researchers at the Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute. Their findings were published online June 25, 2009, by the Journal of Investigative Dermatology.

A virus discovered last year in a rare form of skin cancer has also been found in people with the second most common form of skin cancer among Americans, according to researchers at the Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute. Their findings were published online June 25, 2009, by the Journal of Investigative Dermatology.

The researchers examined tissue samples from 58 people with squamous cell carcinoma (SCC), a highly curable form of skin cancer that is expected to affect more than 200,000 Americans this year.

They identified the virus in more than one-third of the patients and in 15% of the tumors tested. In addition, all of the virus found in tumor cells had a mutation that could enable the viral DNA to integrate into the DNA of the host cell.

“This is indirect evidence that the virus might play a role in causing some cases of squamous cell carcinoma,” says principal investigator Amanda E. Toland, PhD, assistant professor of molecular virology, immunology and medical genetics and a researcher with the Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute.

The virus was first discovered in patients with Merkel cell carcinoma, a rare, aggressive skin cancer that occurs mainly in the elderly and people with a suppressed immune system. The people in the new study all had a healthy immune system.

“Originally it was thought that this virus caused only this rare skin cancer, but our findings indicate that it is a lot more prevalent than we initially thought,” said Dr. Toland.

More Than One-Third Tested Positive
The investigators detected the virus in 26 of 177 SCC samples, 11 of 63 adjacent-skin samples, and 1 sample from a mouthwash. They found no viral DNA in any of the blood samples from 57 patients. In all, 21 of 58 SCC patients, or 36%, tested positive for the virus.

By sequencing the viral DNA from 31 normal and tumor samples, the researchers showed that the same mutation was present in all the viruses tested from tumors, and in 60% of the viruses tested from adjacent healthy-looking tissue.

“That suggests that the virus may develop a mutation that causes it to integrate into host-cell DNA, and, therefore, may play a role in causing the cancer,” said Dr. Toland.

Articles in this issue

Radical Prostatectomy Reigns Supreme
Localized Prostate Cancer: The Battle of Treatment Options Enters the Larger Arena
Ginger
Ginger
More Questions About Neoadjuvant Chemotherapy in Lung Cancer
Neoadjuvant Chemotherapy for Resectable Non–Small-Cell Lung Cancer
Preoperative Therapy for Early-Stage NSCLC: Opportunities and Challenges
FDA Approves First Maintenance Drug Therapy for Advanced Lung Cancer
Accelerated Approval Granted for Bevacizumab in Glioblastoma
New Opioid Pain Reliever Approved With Required Risk-Reduction Plan
FDA Extends Review of Ofatumumab
Degarelix for Advanced Prostate Cancer Gets Trade Name
KRAS Safety Update Added to Panitumumab Prescribing Information
FDA Issues Final Rules to Help Patients Gain Access to Investigational Drugs
SGO White Paper Explores HPV Vaccine’s Impact on Cervical Cancer Prevention
New Fertility Treatment Option Available for Cancer Patients
Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Experts on myeloma
Related Content
Advertisement

The developer submitted their request in writing and anticipates a response from the FDA before the end of Q3 2025.

FDA Accepts Type C Meeting for Doxorubicin-MNA in Basal Cell Carcinoma of the Skin

Tim Cortese
August 22nd 2025
Article

D-MNA achieved complete clinical clearance in 60% of patients, with no dose-limiting toxicities or serious adverse effects observed in those with basal cell carcinoma of the skin.


OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

John M. Kirkwood, MD
April 8th 2022
Podcast

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.


Long-Term Cilta-Cel Follow-Up Shows Curative Potential in Pretreated Multiple Myeloma

Long-Term Cilta-Cel Follow-Up Shows Curative Potential in Pretreated Multiple Myeloma

ONCOLOGY Staff
August 18th 2025
Article

Cilta-cel shows promising long-term efficacy in treating relapsed/refractory multiple myeloma, with significant survival rates and manageable safety profiles.


On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

Matthew Fowler;Emily Hoffman Smith, MD
February 14th 2022
Podcast

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.


Creating Space for Ide-Cel and Finding Sequencing Options in Multiple Myeloma

Creating Space for Ide-Cel and Finding Sequencing Options in Multiple Myeloma

ONCOLOGY Staff
August 16th 2025
Article

Experts debate cutting-edge multiple myeloma treatments, exploring pressing data, the most prominent news, and patient cases.


Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Viviana Cortiana, MS4;Maduri Balasubramanian, MD;Jade Gambill, BS;Diksha Mahendru, MD;Kennedy Itodo, MD;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD
August 15th 2025
Article

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.

Related Content
Advertisement

The developer submitted their request in writing and anticipates a response from the FDA before the end of Q3 2025.

FDA Accepts Type C Meeting for Doxorubicin-MNA in Basal Cell Carcinoma of the Skin

Tim Cortese
August 22nd 2025
Article

D-MNA achieved complete clinical clearance in 60% of patients, with no dose-limiting toxicities or serious adverse effects observed in those with basal cell carcinoma of the skin.


OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

John M. Kirkwood, MD
April 8th 2022
Podcast

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.


Long-Term Cilta-Cel Follow-Up Shows Curative Potential in Pretreated Multiple Myeloma

Long-Term Cilta-Cel Follow-Up Shows Curative Potential in Pretreated Multiple Myeloma

ONCOLOGY Staff
August 18th 2025
Article

Cilta-cel shows promising long-term efficacy in treating relapsed/refractory multiple myeloma, with significant survival rates and manageable safety profiles.


On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

Matthew Fowler;Emily Hoffman Smith, MD
February 14th 2022
Podcast

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.


Creating Space for Ide-Cel and Finding Sequencing Options in Multiple Myeloma

Creating Space for Ide-Cel and Finding Sequencing Options in Multiple Myeloma

ONCOLOGY Staff
August 16th 2025
Article

Experts debate cutting-edge multiple myeloma treatments, exploring pressing data, the most prominent news, and patient cases.


Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Viviana Cortiana, MS4;Maduri Balasubramanian, MD;Jade Gambill, BS;Diksha Mahendru, MD;Kennedy Itodo, MD;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD
August 15th 2025
Article

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.